Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study
N Allen, SR Walker, L Liberti, C Sehgal… - … Open Access Journal, 2016 - cmajopen.ca
Background: The CADTH Common Drug Review was established in 2002 to prepare
national health technology assessment reports to guide listing decisions for 18 participating …
national health technology assessment reports to guide listing decisions for 18 participating …
Analysis of drug coverage before and after the implementation of Canada's Common Drug Review
Background: Canada's Common Drug Review was implemented to provide publicly funded
drug plans (provincial and federal) with a transparent, rigorous and consistent approach for …
drug plans (provincial and federal) with a transparent, rigorous and consistent approach for …
CADTH recommendations as predictors for drug availability in British Columbia and Ontario
D Liden, A Jaksa, K Daniel, Y Ho - Value in Health, 2014 - valueinhealthjournal.com
Objectives The Canadian Agency for Drugs and Technologies in Health (CADTH) conducts
health technology assessments and provides recommendations for drug listing and …
health technology assessments and provides recommendations for drug listing and …
Medicine reimbursement recommendations in Canada, Australia, and Scotland.
OBJECTIVE: This study was undertaken to compare the recommendations made by the
Canadian Common Drug Review (CDR) regarding whether drugs should be listed on …
Canadian Common Drug Review (CDR) regarding whether drugs should be listed on …
[BOOK][B] The effectiveness of the Common Drug Review in Canada's national drug strategy
A Attaran, RG Cartagena, A Taylor - 2012 - aims.ca
Where you live in Canada and your economic status make a big difference to the sort of
prescription medicine you are likely to receive from public health insurance—although that is …
prescription medicine you are likely to receive from public health insurance—although that is …
The common drug review: a NICE start for Canada?
Prescription drugs are one of the fastest growing cost components of modern health care
systems. Efforts to control escalating costs while simultaneously maximizing population …
systems. Efforts to control escalating costs while simultaneously maximizing population …
Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada
FM Clement, A Harris, JJ Li, K Yong, KM Lee… - Jama, 2009 - jamanetwork.com
Context National public insurance for drugs is often based on evidence of comparative
effectiveness and cost-effectiveness. This study describes how that evidence has been used …
effectiveness and cost-effectiveness. This study describes how that evidence has been used …
Common Drug Review recommendations: an evidence base for expectations?
A Rocchi, E Miller, RB Hopkins, R Goeree - Pharmacoeconomics, 2012 - Springer
Abstract Background: The Common Drug Review (CDR) was created to provide a single
process to review the comparative clinical efficacy and cost effectiveness of new drugs, and …
process to review the comparative clinical efficacy and cost effectiveness of new drugs, and …
“Cost-effectiveness” Estimates Result in Flawed Decisionmaking in Listing Drugs for Reimbursement
R West, EK Borden, JP Collet, NSB Rawson… - Canadian journal of …, 2002 - Springer
Background: Facing financial pressures, the provinces and territories have chosen to use
“costeffectiveness” for making decisions about drug listings. This study examines the …
“costeffectiveness” for making decisions about drug listings. This study examines the …
Using economic evaluations to make formulary coverage decisions: so much for guidelines
AH Anis, Y Gagnon - Pharmacoeconomics, 2000 - Springer
Background: It is mandatory for drug manufacturers requesting formulary inclusion under the
British Columbia (BC) provincial drug plan to submit a pharmacoeconomic analysis …
British Columbia (BC) provincial drug plan to submit a pharmacoeconomic analysis …
